- Home
- LVO vs MAIA Comparison
LVO vs MAIA Comparison
Compare LVO & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVO
- MAIA
- Stock Information
- Founded
- LVO 2009
- MAIA 2018
- Country
- LVO United States
- MAIA United States
- Employees
- LVO N/A
- MAIA N/A
- Industry
- LVO Restaurants
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- LVO Consumer Discretionary
- MAIA Health Care
- Exchange
- LVO Nasdaq
- MAIA Nasdaq
- Market Cap
- LVO 68.1M
- MAIA 56.3M
- IPO Year
- LVO N/A
- MAIA 2022
- Fundamental
- Price
- LVO $0.60
- MAIA $1.57
- Analyst Decision
- LVO Strong Buy
- MAIA
- Analyst Count
- LVO 1
- MAIA 0
- Target Price
- LVO $1.50
- MAIA N/A
- AVG Volume (30 Days)
- LVO 615.5K
- MAIA 385.0K
- Earning Date
- LVO 08-13-2025
- MAIA 08-11-2025
- Dividend Yield
- LVO N/A
- MAIA N/A
- EPS Growth
- LVO N/A
- MAIA N/A
- EPS
- LVO N/A
- MAIA N/A
- Revenue
- LVO $100,534,000.00
- MAIA N/A
- Revenue This Year
- LVO N/A
- MAIA N/A
- Revenue Next Year
- LVO $18.93
- MAIA N/A
- P/E Ratio
- LVO N/A
- MAIA N/A
- Revenue Growth
- LVO N/A
- MAIA N/A
- 52 Week Low
- LVO $0.55
- MAIA $1.40
- 52 Week High
- LVO $1.82
- MAIA $3.74
- Technical
- Relative Strength Index (RSI)
- LVO 37.91
- MAIA 46.97
- Support Level
- LVO $0.56
- MAIA $1.50
- Resistance Level
- LVO $0.72
- MAIA $1.64
- Average True Range (ATR)
- LVO 0.05
- MAIA 0.08
- MACD
- LVO 0.00
- MAIA 0.01
- Stochastic Oscillator
- LVO 25.50
- MAIA 40.74
About LVO LiveOne Inc.
LiveOne Inc, formerly LiveXLive Media Inc is a premium internet network devoted to live music and music-related video content. The company has been building an online destination for music fans to enjoy live performances from music venues and music festivals around the world, such as Rock in Rio, Outside Lands Music and Arts Festival, and Hangout Music Festival, as well as original content, artist exclusives, and industry interviews. The Company operates mainly through three segments, PodcastOne, Slacker, and Media Group, with a majority of its revenue derived from the Slacker segment.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.